Objectives: Firstly, to describe the outcome of a series of fetuses with Ebstein’s anomaly (EA) and, secondly, to study the utility of different second-trimester echocardiographic parameters to predict fetal and neonatal mortality. Methods: 39 fetuses with EA diagnosed between 18 and 28 weeks of gestation were included. Fetal echocardiography included the cardiothoracic ratio (CTR); right atrial (RA) area index; displacement of the tricuspid valve (TV); tricuspid regurgitation; pulmonary artery; and ductus arteriosus flow characteristics. Additionally, 2 novel parameters were obtained: the relative RA area ratio (RA area/cardiac area) and the TV displacement index (TVDI, TV displacement distance/longi-tudinal diameter of the left ventricle). Correlation between the echocardiographic variables and the primary outcome of perinatal mortality or survival at 1 year of life was evaluated. Results: From the initial cohort, 8 cases were excluded due to complex congenital heart defects. Termination of pregnancy (TOP) was performed in 15 cases, and fetal death was diagnosed in 3 cases. In the live-born cohort of 13 patients, 4 died in the neonatal period, yielding a perinatal survival rate of 29 and 56%, respectively, after excluding TOP cases. Compared with survivors, nonsurvivors showed a significantly higher CTR (56.7 ± 16.2 vs. 42.6 ± 8.6; p = 0.04), relative RA area ratio (0.39 ± 0.13 vs. 0.25 ± 0.05; p = 0.01), and TVDI (0.62 ± 0.17 vs. 0.44 ± 0.12; p = 0.03) at diagnosis. The best model to predict perinatal mortality was obtained by using a scoring system which included the relative RA area ratio and TVDI (AUC 0.905 [95% CI 0.732–1.000]). Conclusions: Fetuses with a relative RA area ratio ≥0.29 and TVDI ≥0.65 at the second trimester have the highest risk of dying in the perinatal stage.

1.
Hoffman
JI
,
Kaplan
S
.
The incidence of congenital heart disease
.
J Am Coll Cardiol
.
2002
Jun
;
39
(
12
):
1890
900
.
[PubMed]
0735-1097
2.
Hoffman
JI
,
Kaplan
S
,
Liberthson
RR
.
Prevalence of congenital heart disease
.
Am Heart J
.
2004
Mar
;
147
(
3
):
425
39
.
[PubMed]
0002-8703
3.
Freud
LR
,
Escobar-Diaz
MC
,
Kalish
BT
,
Komarlu
R
,
Puchalski
MD
,
Jaeggi
ET
, et al.
Outcomes and predictors of perinatal mortality in fetuses with Ebstein anomaly or tricuspid valve dysplasia in the current era: a multicenter study
.
Circulation
.
2015
Aug
;
132
(
6
):
481
9
.
[PubMed]
0009-7322
4.
Selamet Tierney
ES
,
McElhinney
DB
,
Freud
LR
,
Tworetzky
W
,
Cuneo
BF
,
Escobar-Diaz
MC
, et al.
Assessment of progressive pathophysiology after early prenatal diagnosis of the Ebstein anomaly or tricuspid valve dysplasia
.
Am J Cardiol
.
2017
Jan
;
119
(
1
):
106
11
.
[PubMed]
0002-9149
5.
Hornberger
LK
,
Sahn
DJ
,
Kleinman
CS
,
Copel
JA
,
Reed
KL
.
Tricuspid valve disease with significant tricuspid insufficiency in the fetus: diagnosis and outcome
.
J Am Coll Cardiol
.
1991
Jan
;
17
(
1
):
167
73
.
[PubMed]
0735-1097
6.
Sharland
GK
,
Chita
SK
,
Allan
LD
.
Tricuspid valve dysplasia or displacement in intrauterine life
.
J Am Coll Cardiol
.
1991
Mar
;
17
(
4
):
944
9
.
[PubMed]
0735-1097
7.
Yetman
AT
,
Freedom
RM
,
McCrindle
BW
.
Outcome in cyanotic neonates with Ebstein’s anomaly
.
Am J Cardiol
.
1998
Mar
;
81
(
6
):
749
54
.
[PubMed]
0002-9149
8.
McElhinney
DB
,
Salvin
JW
,
Colan
SD
,
Thiagarajan
R
,
Crawford
EC
,
Marcus
EN
, et al.
Improving outcomes in fetuses and neonates with congenital displacement (Ebstein’s malformation) or dysplasia of the tricuspid valve
.
Am J Cardiol
.
2005
Aug
;
96
(
4
):
582
6
.
[PubMed]
0002-9149
9.
Andrews
RE
,
Tibby
SM
,
Sharland
GK
,
Simpson
JM
.
Prediction of outcome of tricuspid valve malformations diagnosed during fetal life
.
Am J Cardiol
.
2008
Apr
;
101
(
7
):
1046
50
.
[PubMed]
0002-9149
10.
Barre
E
,
Durand
I
,
Hazelzet
T
,
David
N
.
Ebstein’s anomaly and tricuspid valve dysplasia: prognosis after diagnosis in utero
.
Pediatr Cardiol
.
2012
Dec
;
33
(
8
):
1391
6
.
[PubMed]
0172-0643
11.
Wertaschnigg
D
,
Manlhiot
C
,
Jaeggi
M
,
Seed
M
,
Dragulescu
A
,
Schwartz
SM
, et al.
Contemporary outcomes and factors associated with mortality after a fetal or neonatal diagnosis of Ebstein anomaly and tricuspid valve disease
.
Can J Cardiol
.
2016
Dec
;
32
(
12
):
1500
6
.
[PubMed]
0828-282X
12.
Yuan
SM
.
Ebstein’s Anomaly: Genetics, Clinical Manifestations, and Management
.
Pediatr Neonatol
.
2017
Jun
;
58
(
3
):
211
5
.
[PubMed]
1875-9572
13.
Celermajer
DS
,
Cullen
S
,
Sullivan
ID
,
Spiegelhalter
DJ
,
Wyse
RK
,
Deanfield
JE
.
Outcome in neonates with Ebstein’s anomaly
.
J Am Coll Cardiol
.
1992
Apr
;
19
(
5
):
1041
6
.
[PubMed]
0735-1097
14.
Lasa
JJ
,
Tian
ZY
,
Guo
R
,
Rychik
J
.
Perinatal course of Ebstein’s anomaly and tricuspid valve dysplasia in the fetus
.
Prenat Diagn
.
2012
Mar
;
32
(
3
):
245
51
.
[PubMed]
0197-3851
15.
Torigoe
F
,
Ishida
H
,
Ishii
Y
,
Ishii
R
,
Narita
J
,
Kawazu
Y
, et al.
Fetal echocardiographic prediction score for perinatal mortality of tricuspid valve malformation and Ebstein anomaly
.
Ultrasound Obstet Gynecol
.
2019
Apr
;
•••
:
uog.20302
.
[PubMed]
0960-7692
16.
Allan
L
.
Technique of fetal echocardiography
.
Pediatr Cardiol
.
2004
May-Jun
;
25
(
3
):
223
33
.
[PubMed]
0172-0643
17.
International Society of Ultrasound in Obstetrics & Gynecology
.
Cardiac screening examination of the fetus: guidelines for performing the ‘basic’ and ‘extended basic’ cardiac scan
.
Ultrasound Obstet Gynecol
.
2006
Jan
;
27
(
1
):
107
13
.
[PubMed]
0960-7692
18.
Robinson
HP
,
Fleming
JE
.
A critical evaluation of sonar “crown-rump length” measurements
.
Br J Obstet Gynaecol
.
1975
Sep
;
82
(
9
):
702
10
.
[PubMed]
0306-5456
19.
Altman
DG
,
Chitty
LS
.
New charts for ultrasound dating of pregnancy
.
Ultrasound Obstet Gynecol
.
1997
Sep
;
10
(
3
):
174
91
.
[PubMed]
0960-7692
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.